SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022
JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology…
Month: October 2022
Tarsus Announces Transition Plans for Board of Directors
Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors Wendy Yarno will…
SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S
NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS)…
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
New Survey Focused on Access Limitations of Approved Autologous CAR T Therapies Reveals Only 50%…
Akoya to Report Third Quarter 2022 Financial Results on November 7th, 2022
MARLBOROUGH, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The…
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
Integration with the most widely used comprehensive electronic health record will expand clinician and patient…
Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference
Data to be featured in one poster and two oral presentations WATERTOWN, Mass., Oct. 11,…
TeraImmune Receives FDA IND Clearance to Initiate Phase 1/2a Clinical Trial of TI-168 for Treatment of Hemophilia A with Refractory Inhibitors
GERMANTOWN, Md., Oct. 11, 2022 (GLOBE NEWSWIRE) — TeraImmune, Inc., a biotechnology company focused on…
Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments
– Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism;…
TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting
Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting’s Special Poster Collections Demonstrates…
PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers
66% of HPV 16-positive checkpoint inhibitor refractory patients are alive at median follow up of…
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic…
Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development
PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the…
Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film
FDA’s End-of-Phase 2 written response provides positive feedback related to Chemistry, Manufacturing, and Controls (CMC)…
Procaps Announces ESG Commitments and Initiatives with Inaugural Report
MIAMI and BARRANQUILLA, Colombia, Oct. 11, 2022 (GLOBE NEWSWIRE) — Procaps Group (NASDAQ: PROC) (“Procaps”),…
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
Collaboration aims to accelerate drug discovery and advance company’s tRNA synthetase platform SAN DIEGO, Oct….
Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19
BOTHELL, Wash., Oct. 11, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the…
Canary Medical Announces Appointment of Dr. Patrick Verta as Chief Medical Officer
VANCOUVER, British Columbia and CARLSBAD, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) — Canary Medical, a…
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
– BBP-398, an investigational SHP2 inhibitor, is a potentially optimal agent for use in combination…
Nephros Announces Agreement to Sell Pathogen Detection Systems Business and Preliminary Results for Quarter Ended September 30, 2022
Sale Reduces Cash Burn, Includes Seven-Year Earn-Out Provision;Third Quarter Revenue Expected to be Approximately $2.5…